All In Biotech

Drug Trial Radar · NCT06970405

Study of Safety and Effects of Garetosmab in Healthy Obese Men and Post-Menopausal Women

Randomized, Double-Blind, Placebo-Controlled Study of Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of Garetosmab in Men and Post-Menopausal Women With Obesity Who Are Otherwise Healthy

Last checked: Nov 20, 2026Latest source record: Sep 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

May 29, 2025

Primary completion

Jun 8, 2026

Study completion Jun 8, 2026

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
May 14, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is researching an experimental drug called garetosmab, referred to as "study drug". The study is focused on otherwise healthy participants with obesity. The aim of the study is to see how safe and tolerable the study drug is. The study is looking at several other research questions, including: * How much study drug is in the blood at different times * What effect the study drug has on the blood clotting * What effect the study drug has on hormone levels * What effect the study drug has on some organs that produce hormones * What effect hormones have on the side effects produced by the study drug * Whether the body makes antibodies against the study drug (which could change how well the drug works or could lead to side effects)

Conditions

  • Obesity

Interventions

  • GaretosmabDrug

    Administered per the protocol

  • Matching PlaceboDrug

    Administered per the protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment-emergent adverse events (TEAEs)Time frame: Through Week 32
  2. Severity of TEAEsTime frame: Through Week 32

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.